What we treat
- Memory concerns, MCI, and dementia evaluation
- Alzheimer’s-related testing — including amyloid PET
- Disease-modifying treatment — Lecanemab and Donanemab
- Epilepsy and seizure disorders
- Headache and dizziness
- Parkinson’s disease, stroke follow-up, peripheral nerve disorders
Key points
- Amyloid PET is available for selected patients
- Disease-modifying treatment for Alzheimer’s disease is available in eligible cases
- No waiting list — consultations are typically arranged promptly
- Second opinions are accepted
Outpatient reception: Mon–Sat, 8:00–11:30 AM
Booking hours: Mon–Sat, 8:00 AM–4:30 PM
20 minutes from Kansai International Airport (KIX)
About Us
The Neurology Department at Kishiwada Tokushukai Hospital provides diagnosis and
non-surgical treatment of conditions affecting the brain, spinal cord,
peripheral nerves, and muscles.
Patients commonly present with headache, numbness, or dizziness,
as well as conditions such as stroke, Parkinson’s disease, epilepsy,
and Alzheimer’s disease.
Diagnostic evaluation may include amyloid PET when clinically indicated.
Assessment for disease-modifying treatments such as
Lecanemab (Leqembi®) and Donanemab (Kisunla®)
is performed in appropriate cases.
If further investigation or treatment is required, referral to an appropriate facility is arranged,
with follow-up coordinated as needed.
When to visit / When to call ER
Visit this department if:
- Headache or dizziness that is persistent or recurring
- Numbness or tingling in the hands or feet
- Unsteadiness while walking or frequent falls
- Loss of consciousness, fainting, or brief unresponsiveness
- Forgetfulness or difficulty organizing speech
- Double vision, drooping eyelids, slurred speech, or unusual facial movements
- Stiffness, slowed movement, tremor, or involuntary movements
- Memory concerns or suspected early dementia
Call ER immediately if:
- Sudden weakness or numbness of the face, arm, or leg (especially one side)
- Sudden difficulty speaking or understanding speech
- Sudden severe headache, confusion, or loss of consciousness
- Sudden vision loss, severe imbalance, or inability to walk
- Seizure lasting >5 minutes, repeated seizures, or seizure with injury
If stroke or another life-threatening condition is suspected, contact the Emergency Department immediately.
Services
Appointments are required in principle.
A referral letter is recommended but not mandatory.
If available, please bring prior records (imaging reports, medication list, referral letter).
Memory concerns and Alzheimer’s-related testing
It is considered only when clinically indicated
(for example, in suspected early Alzheimer’s disease).
Memory concerns are evaluated through clinical history, cognitive testing, and imaging when appropriate.
Amyloid PET may be used to assess amyloid plaque deposition when clinically indicated.
Testing and treatment options depend on individual medical history and safety considerations.
Disease-modifying treatment: Lecanemab and Donanemab
Lecanemab (Leqembi®) and Donanemab (Kisunla®) may be considered for selected patients with
early Alzheimer’s disease or MCI due to Alzheimer’s disease.
Eligibility is determined through specialist assessment and confirmatory testing (such as amyloid PET and MRI).
Treatment protocols and monitoring requirements vary by case.
Clinical leadership
Neurology care is provided under clinical supervision within the department,
with coordination across related specialties and emergency services when required.
Makoto Izuta, M.D., Ph.D.
(Vice President) — Clinical Neurology / Certified Stroke Specialist
Contact
Contact us from overseas
Start with a brief message to our International Medical Support Department.
Please include your diagnosis, current condition, and the type of consultation or treatment you are seeking.
We will review your case and guide you through the next steps.
Language support for patients in Japan
Language support
- For treatment decisions and informed consent, professional medical interpretation is recommended.
- In-person interpretation can be arranged through JMHC.
- Remote interpretation (30+ languages) is also available via hospital-issued devices.